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INTRODUCTION 
           Gestational diabetes mellitus is defined as `carbohydrate 
intolerance with recognition /onset during pregnancy irrespective of the 
treatment with diet or insulin’. The importance of GDM is that two 
generations are at risk of developing diabetes in the future. Women 
develop type2 DM in future if they get GDM in pregnancy. 
          90% of DM cases seen in pregnancy are GDM. Based on the 
different geographical location, ethnicity, racial groups, the prevalence of 
GDM varies. GDM prevalence in India is 3.8 to 20 percent. The 
prevalence of GDM among urban women is higher when compared to 
rural women. 
           Based on our understanding regarding impact of diabetes in 
pregnancy for future generation, and our increasing ability to reduce the 
pregnancy related complications and postpone ,if not prevent, diabetes 
after GDM, have emphasized the epidemiological and public health 
importance of diabetes in pregnancy. Thus screening for GDM is most 
important in the first trimester to decrease the maternal morbidity and 
foetal morbidity and mortality. 
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            First trimester hba1c levels between 5.3%-≥6% developed GDM 
(Seshiah et al) and hba1c levels ≥6.5% had overt diabetes1. Thus the 
pregestational diabetes pregnancy is detected in the first trimester and 
treated. Hba1c test can be done anytime of the day irrespective of food 
intake. It has less biological variability,  better analytical stability  and 
high reproducibility compared to glucose measurements .So, association 
between first trimester hba1c (cut off value)  and development of GDM 
in pregnancy is studied. 
  
AIMS  
AND  
OBJECTIVES 
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AIM OF THE STUDY 
The aim of this study is to analyse the prognostic value of HBA1C 
test in detecting gestational diabetes mellitus, based on 75gmOGTT 
(DIPSI GUIDELINES) as the reference test. 
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MATERIALS AND METHODS 
STUDY DESIGN: 
Prospective Cohort Study 
SETTING: 
Department Of Obstetrics And Gynaecology, 
Government RSRM Lying In Hospital, 
Government Stanley Medical College. 
DURATION: 
October 2016-September 2017 
SAMPLE SIZE: 
100 
INCLUSION CRITERIA 
 Pregnant women of gestational age 8-13 weeks attending antenatal 
clinic. 
 
MATERIALS  
AND  
METHODS 
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EXCLUSION CRITERIA 
 Overt DM 
 Twins 
 Anemia hb<8g/dl 
GROUP/COHORTS 
LOW RISK COHORT 
 Age<25 
 No history of diabetes in the first degree relative 
 No history abnormal glucose metabolism 
 Weight normal before pregnancy 
 Delivery of normal weight baby 
HIGH RISK COHORT 
 Age>25 
 BMI>30 kg/sqm 
 First degree family member with type 2 diabetes mellitus 
 PCOS 
 Previous pregnancy with GDM 
 Delivery of infant weight>4.5 kg 
 Previous IUD 
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METHODOLOGY 
HBA1C TEST 
 2 ml blood collected in BD vaccutainer k2 EDTA3.6 violet tube for 
hba1c test 
 2 ml of whole blood 
Method: high performance liquid chromatography 
75 gm of OGTT 
 Irrespective of the food intake, 75gm of anhydrous glucose given, 
2 ml blood collected in grey colour glucose tube containing fluoride, 
centrifuged at 3000 rpm and plasma separated. 
 2ml of plasma 
Method: hexokinase method 
100 pregnant women of gestational age 8-13 weeks ,belonging to 
low risk(50) and high risk group(50) are taken for this study.hba1c test 
and 75gm OGTT test is done in all the women in their first 
trimester.Pregnant women with hba1c ≥6.5%,OGTT≥140mg/dl are 
diagnosed pregestational diabetes and treated and they are excluded from 
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the study.In other women  second trimester(24-28 weeks) and third 
trimester OGTT(32-34 weeks) are done to detect GDM.Then they are 
followed up to find the mode of delivery and perinatal outcome.  
 
  
REVIEW  
OF  
LITERATURE 
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REVIEW OF LITERATURE 
DEFINITION: 
Diabetes mellitus is a group of metabolic diseases characterised by 
hyperglycaemia due to  defects in insulin secretion or insulin action or 
both. The chronic hyperglycaemia of diabetes may be associated with 
ketosis, protein wasting and long term damage, dysfunction and failure of 
various organs especially the eyes ,kidneys, nerves, heart  and blood 
vessels. 
NDDG/WHO CLASSIFICATION: 
The National Diabetes Data Group (NDDG) classification system 
was published in 1979 that was later endorsed by WHO study group of 
diabetes mellitus in 1980 as follows: 
 Type 1 diabetes (β cell destruction-leads to insulin deficiency) 
1. Immune mediated 
2. Idiopathic 
 Type 2 diabetes (due to  predominantly insulin resistance with 
relative insulin deficiency or a  predominantly secretary defect 
with insulin resistance) 
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Now it is referred to as ‘METABOLIC SYNDROME’.  
 OTHER SPECIFIC TYPES 
Fibro calculus diabetes mellitus, Drug or chemical or infection 
induced, Genetic defects of β cell function (chromosome 7 0r 12, HNF-
1a: MODY 3 or chromosome 20, HNF-4a: MODY 1) Endocrinopathies 
(acromegaly, Cushing syndrome, pheochromocytoma and 
hyperthyroidism) 
GESTATIONAL DIABETES MELLITUS (GDM) 
PYKE’S CLASSIFICATION 
 Pre-gestational: with or without complications 
 Gestational(GDM) 
PRISCILLA WHITE CLASSIFICATION 
CLASS AGE DURATION VASULAR DISEASE 
A Any Any None 
B >20 <10 None 
C 10-19 &/10-19 None 
D <10 And/or>20  Benign retinopathy 
E Any Any Coronary disease 
F Any Any Nephropathy 
R Any Any Proliferative retinopathy 
RF Any Any Retinopathy & nephropathy 
T Any Any Prior renal transplant 
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Freinkel’s classification: 
According to plasma glucose levels  
A0: FBS: normal, one abnormal OGTT value 
A1: FBS<105, PPBS<120 mg% 
A2: FBS>105-129 and or PPBS>120mg% 
B1: FBS>130mg% 
EFFECTS OF PREGNANCY ON DIABETES MELLITUS 
Pregnancy is a diabetogenic state- reasons are as follows 
 HPL diminishes the action of insulin on peripheral tissues leading 
to insulin resistance. 
 High levels of oestrogen, progesterone and free active  
Cortisol opposes insulin action, producing insulin resistance. 
 Insulinase secreted by placenta 
 In order to meet increased caloric requirements and to save glucose 
for the foetus, lipolysis occurs in the pregnant women. 
Thus pregnancy unmasks diabetes in latent phase, this is known as 
gestational diabetes mellitus. 
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CLINICAL IMPLICATIONS OF THIS EFFECT 
 As insulin requirements increases with pregnancy advancement, 
chemical and clinical diabetes becomes worse. 
 Average renal threshold for glucose in pregnancy is 155±17 mg/dL. 
Because of renal glycosuria in pregnancy titration of insulin dose 
can be done with venous sample rather than urine test. 
 Ketoacidosis is more common in pregnancy at low glucose levels 
because of vomiting, infection and alternate pathway for 
gluconeogenesis. 
 Insulin requirements fall immediately following delivery. 
 Vascular changes of diabetes, especially retinitis, aggravate during 
pregnancy 
 Diabetic nephropathy may progressively worsen. 
EFFECTS OF DIABETES MELLITUS ON PREGNANCY 
Unlike gestational diabetes, pre-gestational diabetes has a 
significant impact on pregnancy outcome: both maternal and foetal. 
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Maternal complications: 
1. During pregnancy: spontaneous abortion if uncontrolled diabetes, 
infection, preterm delivery, preeclampsia, Polyhydramnios, 
chorioamnionitis. 
2. During labour: prolonged labour, uterine inertia, shoulder 
dystocia, increased operative interference. 
3. In puerperium: postpartum haemorrhage, sepsis, failing lactation, 
postpartum endometritis. 
FETAL COMPLICATIONS: 
 Diabetic embryopathy 
CVS: VSD, transposition, ASD, coarctation of aorta 
CNS: anencephaly, holoprosencephaly, encephalocoele 
Skeletal: caudal regression syndrome 
Genitourinary: renal agenesis, ureteral duplications 
GIT: anal atresia, trachea oesophageal atresia 
 Stillbirths 
 Respiratory distress syndrome 
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 Foetal macrosomia: maternal hyperglycaemia leads to foetal 
hyperglycemia that in turn causes foetal hyperinsulinemia. Foetal 
hyperinsulinemia results in excessive foetal growth and adipose tissue. 
This is called Pederson hypothesis. 
 Hypothermia 
 Hyperbilirubinemia 
 Hypoglycaemia 
 Hypocalcaemia 
 Hyper viscosity syndrome 
 Apnoea 
 Bradycardia 
 Hypertrophic cardiomyopathy 
 Overall perinatal mortality increases about 2-3 times 
GESTATIONAL DIABETES MELLITUS 
DEFINITION: 
Is defined as glucose intolerance of any degree with onset or first 
recognition during pregnancy. The definition applies regardless of 
whether insulin or only diet modification is used for treatment or whether 
the condition persists after pregnancy.90% cases of   DM in pregnancy 
are GDM. 
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PREVALENCE: 
The prevalence of GDM varies worldwide and among different 
racial and ethnic groups within a country. The prevalence of GDM in 
India varied from 3.8 to 21%.GDM has been found to be more prevalent 
in urban areas than in rural areas. 
PATHOPHYSIOLOGY: 
GDM occurs when the woman’s beta cell function is not able to 
overcome the antagonism created by the anti-insulin hormones of 
pregnancy and the increased fuel consumption required provide for the 
growing foetus. 
RISKS: 
GDM mothers are at high risk for gestational hypertension,  
pre-eclampsia, UTI, caesarean delivery and future diabetes. Fetal 
complications such as macrosomia, neural tube defects, neonatal 
hypoglycaemia, hypocalcaemia, hypomagnesaemia, Hyperbilirubinemia, 
birth trauma, prematurity syndromes and subsequent childhood and 
adolescent obesity. 
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SCREENING AND DIAGNOSIS: 
HISTORY AND EXAMINATION: 
Risk assessment has to be done in the first antenatal visits. The risk 
factors are divided into two categories, high risk and low risk. 
RISK FACTORS (indications for screening) 
HIGH RISK 
 Age ≥25 yrs. 
 Family history of diabetes in first degree relative 
 BMI>25 
 Bad obstetric history: previous history of unexplained perinatal 
loss, intrauterine foetal death, large for gestational age infant, 
congenitally malformed infant, polyhydramnios and pregnancy 
induced hypertension. 
 Pregnant women are member of ethnic group with high prevalence 
of GDM E.g.: Indian women. 
LOW RISK (all criteria to be met) 
Age <25yrs. 
Women normal before pregnancy BMI<25 
No known diabetic in the first degree relative 
No previous abnormal glucose tolerance 
No  previous  poor obstetric outcome 
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SCREENING 
Insulin is detectable in the foetal pancreas as early as 9 weeks after 
conception. An increase in pancreatic beta cell mass and insulin secretion 
in the foetus occurs by the 16
th
 week of gestation, in response to maternal 
hyperglycemia. The priming of pancreatic beta cells may account for the 
persistence foetal hyperinsulinemia throughout the pregnancy and the risk 
of accelerated foetal growth, even when the mother good glycaemic 
control in later pregnancy. Thus test to be done to diagnose GDM in the 
first trimester itself. Since GDM in pregnancy is asymptomatic and since 
hyperglycemia is teratogenic, screening for carbohydrate intolerance 
should ideally be done in all pregnant patients. As Indian population are 
at high risk of developing GDM, universal screening to be done.  
TIMING OF SCREENING: 
General population-24-28 weeks 
High risk population: 
First trimester <16 weeks, if negative then 24-28 weeks and 32-34 weeks. 
METHODS OF SCREENING: 
NEW 2011ADA CRITERIA FOR diagnosing GDM 
It is based on the HAPO study
25
. 
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Single step 75gm of OGTT, with plasma glucose measurement 
fasting and at 1 and 2hr is performed at 24-28 weeks. It should be 
performed in the morning after an overnight fast of atleast 8 hrs but not 
more than 14 hours and 3 days of unrestricted diet.  
The values for diagnosis of GDM 
Fasting>95mg/dl 
1 hr >180m/dl or 
2hr>155m/dl 
A single abnormal value merits a diagnosis of GDM. 
WHO method 
 OGTT with 75gm glucose with a threshold plasma glucose 
concentration of greater than 140mg/dL after two hours is the criteria for 
diagnosing GDM. 
DIPSI METHOD 
The diabetes in pregnancy study group India has reported practical 
guidelines for Indian population. 
75g of glucose is taken orally irrespective of the last meal and after 
2 hours venous blood sample is taken and estimation of plasma glucose 
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by GOD-POD method. GDM is diagnosed if 2 hour plasma glucose is 
>140mg/dl. `Gestational glucose intolerance’ denotes values between 120 
and 139mg/dl. 
INTRAVENOUS GLUCOSE TOLERANCE TEST 
It is more sensitive than OGTT and useful  when vomits with 
OGTT.25 g of glucose is given as 50% dextrose intravenously in 2-4 
min; and blood is collected at 10,20,30,40,50,and 60 min. Then K value 
is calculated as K=69.3/T1/2.K value <1.5 in pregnancy suggests diabetes 
mellitus. 
GLYCOSATED HBA1C 
It is formed in a non-enzymatic pathway by haemoglobin’s normal 
exposure to high plasma levels of glucose. In the normal 120 days life 
span of RBC, glucose molecules react with haemoglobin, forming 
glycated haemoglobin. Once glycated haemoglobin is formed it remains 
the same till its lifespan. 
Thus hba1c level is proportional to average blood glucose 
concentration over a period of 4 weeks to 3 months. An elevated level 
during first and early second trimester bears a positive correlation with 
congenital malformations. Regular monitoring of hba1c level is essential 
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in all diabetes regardless of type of therapy. Glycosated hbA1c is most 
useful for preconceptional counselling and to predict foetal outcome.it is 
not useful in day to day adjustment   of the insulin dosage. 
In 2010 American Diabetes Association standards of medical care 
in diabetes added hba1c ≥6.5% as another criteria for diagnosing 
diabetes. 
It needs a single non-fasting blood sample and it is measured by 
high performance liquid chromatography or by immunoassay. 
If the glucose intolerance is identified in the first trimester, it will 
help in differentiating pre-gestational diabetes from gestational diabetes 
mellitus. If the hba1c level is >6% she is likely to be a pre-gestational 
diabetes. The American Diabetes Association(ADA) and European 
Association for the Study of Diabetes(EASD) and International Diabetes 
Federation(IDF) have agreed that in the future hba1c is to be reported in 
the International Federation of Clinical Chemistry (IFCC) units 
(6.5%=48mmol/mol)
16
. 
SERUM FRUCTOSAMINE 
It is useful to assess the short term state of maternal glucose control 
during the past two weeks. 
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URINE GLUCOSE 
Renal glycosuria is neither diagnostic nor prognostic value since 
renal threshold in pregnancy is reduced. Glycosuria is a common finding 
in pregnancy due to increased GFR so it is unreliable as a diagnostic test. 
Some studies have shown that pregnant women with renal glycosuria 
develop preterm labour, macrosomia in the foetus, asymptomatic bacteria 
or recurrent UTI. 
MANAGEMENT 
Principles of management for both gestational and  
Pre-gestational diabetes are discussed below 
PRECONCEPTIONAL COUNSELLING 
Pregnancies in diabetic women should be planned preconception 
ally and there must be good control prior to conception with hba1c within 
normal range. Folic acid should be supplemented. NICE GUIDELINES 
states that hba1c >10% is contraindication for pregnancy. Impaired renal 
function as measured by a serum creatinine >0.2mmol/L is also a 
contraindication for pregnancy.it is important to identify and treat any 
pre-existing retinopathy in diabetic women considering pregnancy. 
Thyroid function test screening is recommended in type 1 diabetes 
pregnant women. 
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ANTENATAL MANAGEMENT 
MEDICAL MANAGEMENT 
The goal of medical management is to reduce the incidence of 
congenital malformations and prevent perinatal morbidity and mortality 
by normalizing the glycaemic status. Recent studies suggest that 
aggressive treatment should be administered for any diagnosis of GDM. 
TEAM APPROACH 
A multidisciplinary team approach includes a diabetologist, 
obstetrician, dietician, nurse, neonatologist and perinatologist are needed 
for the management for diabetic women. Tight glycaemic control both 
day and night is needed. 
EDUCATION OF PATIENTS 
Women must be taught about the effects of GDM on her foetus and 
on her health 
 The diet and exercise methods 
 Self-monitoring of blood glucose regularly 
 Self-administration of insulin by her and adjustment of insulin 
doses regularly 
 Identification and treatment of hypoglycaemia correctly 
 Incorporation of safe physical activity regularly 
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MEDICAL NUTRITIONAL THERAPY 
The main treatment of GDM is nutritional counselling and dietary 
restriction. Gestational diabetes class A0, A1 can be controlled with diet 
alone. The meal plan should give adequate calories and nutrients to meet 
the pregnancy needs. 
The expected weight gain during pregnancy is 300-400g per week 
and total weight gain is 10 to 12 kg by full term. Hence the diet plan 
should provide sufficient calories to maintain adequate nutrition for the 
mother and foetus to avoid excess weight gain and also postprandial 
hyperglycaemia. 
Achieving a weight gain <500g/week will attain euglycemia and 
omit the risk of macrosomia. 
Weight gain should be appropriate to maternal BMI. Hypo caloric 
diets in pregnancy can cause accelerated starvation and thereby produce 
ketosis. 
A well balanced high protein diet providing 2g of protein per kg 
body weight and 45-50% of carbohydrates and 30-35%of fats should be 
provided. Ingestion of carbohydrates with low glycaemic index is 
preferred because they provide good glycaemic control and better serum 
lipid profile. Frequent small meals which include three meals of breakfast 
(10% of total calorie intake), lunch (30% of total calorie intake) and 
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dinner (30% of total calorie intake) and three snacks including a pre 
bedtime snack (30% of total calorie intake) are essential to maintain 
euglycemia throughout day and night. Redistribution is the main principle 
for diet control. 
Complex carbohydrates like grains, pulses, cereals, beans and salad 
should be consumed whereas simple refined carbohydrates like sugar, 
honey, Maida and jaggery should be avoided. Patient must consume one 
fresh fruit every day. The diet should be rich in fibre. Soluble fibres 
reduce glucose absorption from intestine, slowdown rise of postprandial 
blood glucose and decrease requirement of postprandial insulin. Other 
nutritional requirements like iron 60-100 mg/day, folic acid 1gm and 
calcium 1-3 g/day should also be provided. 
Medical nutrition therapy is done initially for 2 weeks. If it fails to 
achieve control FBS≥95mg/dl, 2 hour PPBS≥120mg/dl then insulin may 
be initiated. Random blood glucose >180mg/dl and hba1c>12% are also 
considered as indications for starting insulin treatment. 
As a part of the MNT, pregnant diabetic women are advised to 
correctly distribute their calorie consumption especially during breakfast 
by splitting breakfast into two equal halves with two hours apart; peaking 
of morning blood glucose level is reduced. 
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Calorie requirement in GDM to maintain euglycemia  
(Jovanovich and Peterson) 
Calorie requirement for present pregnant weight 
Normal weight women 30 kcal/kg/24h 
Overweight women(120-150% 
ideal body weight) 
24 kcal/kg/24h 
Morbidly obese 
women(>150%ideal body 
weight) 
12 to 15 kcal/kg/24h 
Underweight women(<80% ideal 
body weight) 
40 kcal/kg/24h 
    
EXERCISE THERAPY 
Cardiovascular conditioning has both acute and long term effects 
on insulin sensitivity, insulin secretion and glucose metabolism. Exercise 
is recommended if there is no medical or obstetric contraindication for 
the exercise program.It is recommended that they exercise at least 3 days 
per week, preferably for 0.5-1 hr. The exercise should be anaerobic and 
its intensity can be calculated at 60% of the maximal heart rate as 
determined by the patient age. 
The maximal heart rate=222-patients age. Swimming, walking are 
preferred types because they are well tolerated by pregnant women and 
most patients enjoy them. 
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INSULIN THERAPY 
Diabetes on insulin therapy in pre-pregnant state and gestational 
diabetic patients not responding to two weeks of medical nutrition 
therapy require insulin. Only 15% of GDM patients will require insulin. 
Insulin dose 
Pre-gestational diabetes (PGDM) 
For management of pre-gestational diabetes, weight based insulin 
regimes are commonly employed in pregnancy the insulin requirements 
in pregnancy may gradually increase: 
 0.7units/kg/day at 6-8 weeks 
 0.8units/kg at 18-26 weeks 
 0.9 units/kg at 26-36 weeks 
 1.0units /kg at 36-40 weeks  
If the total insulin required is <50units/day, it may be given in a 
single morning dose in the ratio of short acting (regular/act rapid) to 
intermediate acting (NPH) of 1:2.if higher doses of insulin (>50 units) are 
required, a minimum of two injections (in short acting to intermediate 
acting of 1:2) before breakfast and before dinner are needed. 
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Usually women with GDM do not require >20 units of insulin per 
day for glycaemic control. Start with premix insulin 30/70: 
Starting dose: 4 units before breakfast 
Every 4th day increase 2 units till 10 units 
If FPG remains >90mg/dl advise 6 units before breakfast &4 units 
before dinner. 
Review with blood sugar test: adjust dose further 
If GDM is diagnosed in the third trimester, MNT is advised for a 
week. Insulin should be initiated if MNT fails after a week. A significant 
fall in insulin requirement in the third trimester is an ominous sign 
suggesting foetal compromise and requires intensive surveillance tests. 
INSULIN PROTOCOLS 
REGIMEN 1 
The total insulin requirement is given in two doses, given before 
breakfast and dinner respectively. The ratio of intermediate to short 
acting insulin in the morning is 2:1; in the evening it is 1:1.alternatively 
premixed insulin’s may be employed.  
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REGIMEN 2 
Some GDM patients fail to achieve optimal glucose levels at 
lunchtime with regimen 1 a small dose of short acting insulin before 
lunch, prelunch value decides the dose. For every 30 mg/dl increase over 
the desired value of 90 mg/dl, 1 unit of insulin needs to be administered. 
REGIMEN 3 
25%of total dose before breakfast(short acting),25% of the total 
dose before lunch(short acting) and remaining 50% so total dose is given 
before dinner(intermediate acting). 
REGIMEN 4  
It ensures better night control by giving fourth injection at bedtime, 
besides short acting insulin before breakfast, lunch and dinner. 
REGIMEN 5 
The continuous infusion pumps are programmed for basal secretion 
and delivery of required bolus before major meals. They should be 
motivated that they can develop complications such as hyper or 
hypoglycaemia and local infections. 
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Insulin therapy needs individualisation.one must have tight 
glycaemic control especially from 30 weeks. This is possible because 
pregnant women at rest in hospital tolerate hypoglycaemia better and are 
asymptomatic even at glucose levels of 30mg%  
CHOICE OF INSULIN 
Recombinant human insulin is most preferred as it is least 
immunogenic. Insulin analogs are developed by modifying the amino 
acid sequence. Rapid acting insulin analogues have been found to be safe 
and effective in achieving targeted postprandial glucose value during 
pregnancy. Lispro the first analogue to get category B approval by US 
FDA and aspart have been used in pregnancy. 
ROUTE OF ADMINISTRATION 
Insulin should be administrated subcutaneously. Pen injectors are 
very good and the patient’s acceptance is also good . Before injection, the 
vial or pen should be gently rolled in the palms of the hands to resuspend 
the insulin. Rotation of insulin injection site is important to prevent 
lipohypertrophy or lipoatrophy. The abdomen has the fastest rate of 
absorption, followed by the arms, thighs and buttocks. 
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TIMING OF ADMINISTRATION 
Administer short acting insulin before meals to reduce post-meal 
hyperglycemia. Give regular insulin 30 minutes before eating. Give lispro 
and aspart immediately before eating. They are very fast acting, so 
hypoglycaemia can occur if food is not taken shortly after their 
administration. MNT is also advised.  
ORAL HYPOGLYCEMIC AGENTS 
Oral hypoglycaemic agents are gaining recognition as a safe and 
effective alternative to insulin when diet alone fails to optimize the 
glycaemic profile in gestational diabetes. 
Data suggests that glyburide and metformin are safe and effective 
in gestational diabetes mellitus. Oral hypoglycaemic agents can be used 
for patients whose fasting plasma glucose levels remain above 95mg/dl 
(or PPBS>120mg/dl, or hba1c≥8%) despite diet therapy, and for those 
who are not appropriate for diet therapy alone. 
Glyburide is used in the management of GDM and pre-existing 
type 2 DM in the starting dose of 2.5 mg in the morning and after first 
week add 2.5mg in the evening. If necessary the morning and evening 
dose is increased by 5 mg to reach a maximum of 10mg in the morning 
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and evening (20mg/day).glyburide is the only drug that can be safely 
recommended at this time. Although some studies have reported 
favourable perinatal outcomes with the use of metformin drug for the 
treatment of gestational diabetes, more clinical trials and follow up 
studies are needed before this therapy can be recommended. Metformin 
primarily used up to 14 weeks in PCOS, shown to be safe throughout 
pregnancy in efficacy trial (rowan) 
Studies have shown no difference in maternal or neonatal 
outcomes with glyburide or metformin compared with insulin. Metformin 
and many other hypoglycaemic and antihyperglycaemic agents may, in 
the future offer alternatives to glyburide with comparable and greater 
efficacy. However, current research has not provided the evidence for 
their safe use in pregnancy. 
SELF MONITORING OF CAPILLARY BLOOD GLUCOSE 
This method of self-evaluation using capillary blood samples has 
become one of the most important tools are monitoring and improving 
glycaemic control and making adjustments in the diabetes therapeutic 
regimen. SMCBG is a relatively painless procedure that involves pricking 
the finger with a lancet to obtain a drop of blood that is placed on a test 
strip. Reagents on the test strip contain an enzyme that causes glucose to 
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react with a dye to produce a colour change. The colour intensity is 
proportional to the amount of glucose present. The test strip is placed in a 
small hand held meter that quantifies glucose concentration using 
reflectance spectrometry. Typically, plasma venous glucose measurement 
are within 15% of the results of whole blood capillary glucose 
determinations.it is performed four times a day(fasting, 2 hr after each 
meal and bed time);additionally a 3 am measurement is done, if there is a 
question of morning rebound hyperglycemia (somogyi effect)or early 
morning insulin depletion(dawn phenomenon). 
Continuous glucose monitoring system (CGMS) traces the blood 
sugar level continuously for 24-72 hours, which helps in tailoring the 
treatment schedule.CGM can reveal unphysiological fluctuations in the 
maternal plasma glucose level, which are not recognised by SMCBG. 
MONITORING OF GLYCEMIC CONTROL 
 Until  the 28th week of gestation  monitoring of both FBS and 
PPBS once a month and at other time of the day as the consultant 
decides. 
 After 28th week of gestation, monitoring should be  done more 
frequent at least once in 2 weeks, if needed more frequently. 
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 After 32 weeks of gestation  monitoring should be done once a 
week till delivery. In high risk pregnant women frequent 
monitoring may be done with SMBG. 
TARGET BLOOD GLUCOSE LEVELS 
Very tight glycaemic control, similar to targets in diabetic 
pregnancies, is the primary goal. 
 
Glucose values for adequacy of control 
Fasting glucose 60-90(or95)mg/dl 
Premeal glucose 60-100mg/dl 
1 hour postprandial value <140mg/dl 
2 hr value <120mg/dl 
Bedtime glucose <120mg/dl 
2:00-6:00am values 60-120mg/dl 
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Maternal monitoring protocol 
Test Frequency 
HBA1C Every 4-6 weeks 
Glucose During weekly or biweekly in physician’s 
office;finger stick at home,4-8 times daily  
Urine ketone When any finger stick blood glucose level 
>200mg/dl 
Urinalysis During biweekly office visits; culture if 
significant pyuria is present. 
Kidney function 24-hour creatinine clearance; total protein; 
uric acid each trimester 
Thyroid function Baseline, free T4,TSH,antimicrosomal 
antibodies, repeat if needed 
Eye status Fundoscopy in first trimester and then 
monthly till term if retinopathy is present 
Frequency of testing maternal status during pregnancy for women 
with pre-existing diabetes. 
 
OBSTETRIC MANAGEMENT 
FETAL EVALUATION 
AT 18 to 20 weeks targeted ultrasound to be done to rule out 
congenital anomalies .Foetal echocardiography should be done at around 
20-24 weeks for viewing all the four chambers of the heart. 
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Foetal surveillance should begin between 28 and 32 weeks. 
Foetal kick count, non-stress test, modified biophysical profile are 
the foetal surveillance tests. 
In uncomplicated cases, patients are to be admitted 2 weeks before EDD. 
Early hospitalization is required for  
 Diabetic stabilisation 
 Complications e.g.: gestational hypertension, preeclampsia, 
polyhydramnios. 
 For termination of pregnancy  
Antenatal steroids to be given for foetal lung maturity and insulin 
must be simultaneously increased to maintain euglycemia. 
INTRANATAL MANAGEMENT 
Delivery to be planned in a tertiary care hospital. 
TIMING OF DELIVERY 
Once, GDM is diagnosed there is increased obstetric intervention, 
induction of labour or caesarean section. In well controlled diabetic 
pregnancies, no good evidence for routine delivery before 40 weeks. 
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Delivery before full term is indicated in case of macrosomia, 
Polyhydramnios, poor metabolic control or other obstetric indication. 
Induction of labour is done if foetus doesn’t have macrosomia and 
the cervix is capable of being induced. 
Insulin administration in labour 
In labour, insulin requirement decreases, so morning dose of 
insulin to be skipped and for attaining tight control intravenous insulin 
should be given. 
Plasma glucose at time of 
onset of labour (mg/dl) 
Insulin/iv fluids 
<70  5%DNS-100 ml/hr 
90-120 NS-100 ml/hr 
120-140 NS-100 ml/hr +4 U of regular insulin 
140-180 NS-100 ml/hr+6 U of regular insulin 
>180 NS-100 ml/hr+8 U of regular insulin 
 
INDUCTION OF LABOUR 
 NO breakfast is given on the day of induction 
 5% DNS is infused at a constant rate of 100-125ml/hr for basic 
calorie requirements. Blood glucose is monitored hourly by 
glucometer and intravenous insulin is given as per sliding scale. 
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 ARM is done 
 In order to augment labour, oxytocin infusion to be started in 
separate infusion bottle and pump. If labour fails or doesn’t 
progress satisfactorily, then patient to be taken up for LSCS. 
Continuous Foetal monitoring and partogram are mandatory. 
INDICATIONS FOR LSCS 
 Previous history of IUD 
 Elderly primigravida 
 Breech or unstable presentation 
 Macrosomic baby(EFW≥4 KG) 
 Polyhydramnios, preeclampsia 
 Diabetes which is difficult to control 
 Induction of labour fails 
LSCS PROCEDURE 
On day of surgery, breakfast and morning dose of insulin is 
omitted. Intravenous insulin infusion using 5% DNS is started as above. 
Insulin infusion is stopped once placenta is removed. Spinal or epidural 
anaesthesia is preferred. Post op blood glucose to be monitored and 
insulin dose to be altered accordingly. 
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POSTNATAL MANAGEMENT 
Insulin requirements fall significantly after delivery, so reduce 
dose by 50-70% immediately and then adjust it according to glucose level 
in the blood 24 hours after delivery. Restart insulin if FBS>110mg% or 
PPBS>160mg%.majority of people does not need insulin for 48-96 hours 
after delivery. 
Breastfeeding to be commenced immediately after delivery as it 
has a protective effect in preventing type 2 diabetic in the future of 
gestational diabetic women. 
FAMILY PLANNING ADVICE 
Newer low dose combined pills containing third or fourth 
generation progestin can be used. Progesterone only pill can be used. 
Barrier methods are preferred. After two healthy babies permanent 
sterilisation to be planned. 
NEONATAL MANAGEMENT 
The neonates of mothers with GDM are also at risk of developing 
complications similar to infant of overt diabetic mothers, particularly 
macrosomic babies (>3.5kg in Indian population), at the time of delivery 
neonatologist must be present. 
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The following actions are to be done  when  the baby  is born 
 Early clamping of the umbilical  cord 
 Evaluate vital signs and  APGAR at 1 and 5 minutes 
 To follow the steps in neonatal resuscitation protocol like, dry the 
baby, receive the baby in pre-warmed incubator 34 degrees C, clear 
the oropharynx and nose of mucus and later empty the stomach. 
 Perform initial physical examination to rule out major congenital 
anomalies 
 Monitor infant  heart rate, respiratory rate, colour and motor 
behaviour for first 24 hours.  
 Start early breast feeding  within  4-6 hrs after delivery. 
 Promote bonding 
 Baby may be kept in NICU for early diagnosis and management of 
complications like 
 Asphyxia, RDS in first 3 days 
 Hypoglycaemia(capillary bold glucose level should be monitored 
at 1,2 and 4 hours after birth) 
 Hypothermia 
 Hyperbilirubinemia 
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PERINATAL MORTALITY 
Stillbirth occurs in the last 6 weeks and it can be related to 
maternal ketoacidosis, foetal hypoxia and foetal hypoglycaemia. 
Neonatal death are due to RDS, foetal hypoglycaemia, polycythaemia or 
jaundice. 
FOLLOW UP 
According to IADPSG guideline all women diagnosed GDM or 
overt diabetic during pregnancy must undergo postpartum 75 gram 
OGTT 6-12 weeks after delivery. 
Then they are reclassified into the following groups 
 Diabetes 
 Impaired glucose tolerance 
 Impaired fasting glucose 
 normoglycemia 
Approximately 81 to 94% of women with GDM return to 
euglycemia after delivery. If normal, then assess every 3 years. 
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PROGNOSIS 
Perinatal morbidity is appropriate yardstick to measure the 
successful management of GDM patients.”50% of GDM women will 
develop type 2 DM within 15 years of delivery”. The risk of developing 
recurrence of GDM in subsequent pregnancy is 30-50%. 
 
 
 
  
RESULTS 
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RESULTS AND ANALYSIS 
TABLE-1  
        AGE*COHORT GROUPS 
 
Group Statistics 
 
 Cohort Group N Mean 
Age in years 
 
Low 50 22.04 
High 50 26.46 
 
CHART-1 
 
 
 
TABLE 1  This table depicts the distribution of age among the 
low and high risk groups. The mean age in low risk group is 22 yrs and in 
high risk group  is 26yrs. 
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TABLE 2 
 
OBSTETRIC CODE*COHORT GROUP 
 
Obstetric 
code 
 
 
Cohort Group 
Total P Value 
Low High 
Primi 
 
 
Count 27 18 45  
 
 
 
 
 
 
0.070 
% within Obstetric code 60.0% 40.0% 100.0% 
% within Cohort Group 54.0% 36.0% 45.0% 
Multi 
 
 
Count 23 32 55 
% within Obstetric code 41.8% 58.2% 100.0% 
% within Cohort Group 46.0% 64.0% 55.0% 
Total 
 
 
Count 50 50 100 
% within Obstetric code 50.0% 50.0% 100.0% 
% within Cohort Group 
100.0% 
100.0
% 
100.0% 
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CHART 2 
 
 
 
 
 
TABLE 2 : This table depicts obstetric status is not significant 
between the two groups. 
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TABLE 3 
 
BMI*COHORT GROUP 
 
 
BMI 
 
Cohort Group N Mean 
Low 50 23.12 
High 50 26.44 
 
 
 
CHART 3 
 
 
 
 
 
TABLE 3: This table shows the mean BMI in low risk group is 
23.12 and for high risk group is 26.44. 
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TABLE 4 
Mode of Delivery * Cohort Group 
 
Crosstab 
 
Mode of 
Delivery 
 
Cohort Group 
Total P Value 
Low High 
LSCS 
 
 
Count 19 23 42  
 
 
 
 
 
 
 
 
0.218 
% within Mode of 
Delivery 
45.2% 54.8% 100.0% 
% within Cohort Group 38.0% 51.1% 44.2% 
Labour 
natural 
 
 
Count 31 21 52 
% within Mode of 
Delivery 
59.6% 40.4% 100.0% 
% within Cohort Group 62.0% 46.7% 54.7% 
Outlet 
forceps 
 
 
Count 0 1 1 
% within Mode of 
Delivery 
.0% 100.0% 100.0% 
% within Cohort Group .0% 2.2% 1.1% 
Total 
 
Count 50 45 95 
% within Mode of 
Delivery 
52.6% 47.4% 100.0% 
% within Cohort Group 100.0% 100.0% 100.0% 
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CHART 4 
 
 
 
 
TABLE 4 : This table  depicts the  distribution of mode of delivery 
between the groups and it shows the mode of delivery is not significant. 
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TABLE 5 
 
BIRTHWEIGHT *COHORT  STUDY 
 
 
Cohort 
Group 
N Mean 
Std. 
Deviation 
P VALUE 
Baby Birth 
Weight 
Low 
50 2.95558 .365445 
0.002* 
 High 45 3.16031 .584446 
 
 
CHART 5 
 
 
 
 
 
TABLE 5:This table depicts distribution of birth weight of the two 
groups. Birth weight is highly significant. The mean birth weight in low 
risk group and high risk group are 2.9kg  and 3.16 kg respectively. 
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TABLE 6 
Baby Birth Weight * GDM * Cohort Group Cross tabulation 
 
Cohort 
Group 
 
Baby 
birth 
weight 
 
 
GDM Total 
P 
value 
No 
GDM 
GDM  
 
Low 
 
 
 
 
 
 
<= 3.6 
 
 
Count 47  47 
% within Baby 
Birth Weight 
100.0%  100.0% 
% within GDM 94.0%  94.0% 
3.6-4.0 
 
 
Count 3  3 
% within Baby 
Birth Weight 
100.0%  100.0% 
% within GDM 6.0%  6.0% 
Total 
Count 50  50 
 
% within Baby 
Birth Weight 
100.0%  100.0% 
% within GDM 100.0%  100.0% 
High 
 
 
 
 
 
 
 
 
 
<= 3.6 
 
 
Count 20 14 34  
 
 
 
 
 
 
 
 
0.003* 
% within Baby 
Birth Weight 
58.8% 41.2% 100.0% 
% within GDM 100.0% 56.0% 75.6% 
3.6-4.0 
 
 
Count 0 8 8 
% within Baby 
Birth Weight 
.0% 100.0% 100.0% 
% within GDM .0% 32.0% 17.8% 
> 4.0 
 
 
Count 0 3 3 
% within Baby 
Birth Weight 
.0% 100.0% 100.0% 
% within GDM .0% 12.0% 6.7% 
Total 
 
 
 
 
 
Count 20 25 45 
% within Baby 
Birth Weight 
44.4% 55.6% 100.0% 
% within GDM 100.0% 100.0% 100.0% 
49 
 
 
 
 
CHART 6 
 
 
 
 
TABLE 6: This table shows GDM and  birth weight is significant 
in high risk groups.32% weighed 3.6-4 kg and 12% weighed more than 4 
kgs. 
 
  
Cohort Group=Low
Baby Birth Weight
3.6-4.0<= 3.6
C
ou
nt
50
40
30
20
10
0
50 
 
TABLE 7 
Baby Birth Weight * GDM Cross tabulation 
 
Baby birth 
weight 
 GDM 
Total 
 
P value 
 
No 
GDM 
GDM 
<0.001** 
<= 3.6 
  
  
Count 67 14 81 
% within Baby Birth 
Weight 
82.7% 17.3% 100.0% 
% within GDM 95.7% 56.0% 85.3% 
3.6-4.0 
  
  
Count 3 8 11 
% within Baby Birth 
Weight 
27.3% 72.7% 100.0% 
% within GDM 4.3% 32.0% 11.6% 
> 4.0 
  
  
Count 0 3 3 
% within Baby Birth 
Weight 
.0% 100.0% 100.0% 
% within GDM .0% 12.0% 3.2% 
 
Total 
 
 
Count 70 25 95 
% within Baby Birth 
Weight 
73.7% 26.3% 100.0% 
% within GDM 100.0% 100.0% 100.0% 
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CHART 7 
 
 
 
 
 Table 7 : This table shows 11.6%  of GDM babies weighed 3.6-4 
kg and 3.2% of GDM babies weighed >4 kg. 
  
Cohort Group=High
Baby Birth Weight
> 4.03.6-4.0<= 3.6
C
ou
nt
30
20
10
0
GDM
No GDM
GDM
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TABLE 8 
Apgar - 1 * Cohort Group 
 
Apgar 1 
 
 
Cohort Group Total 
 
P 
value 
Low High 
0.023* 
5 
 
 
Count 0 1 1 
% within Apgar - 1 .0% 100.0% 100.0% 
% within Cohort Group .0% 2.2% 1.1% 
6 
 
 
Count 1 9 10 
% within Apgar - 1 10.0% 90.0% 100.0% 
% within Cohort Group 2.0% 20.0% 10.5% 
7 
 
 
Count 44 32 76 
% within Apgar - 1 57.9% 42.1% 100.0% 
% within Cohort Group 88.0% 71.1% 80.0% 
8 
 
 
Count 5 3 8 
% within Apgar - 1 62.5% 37.5% 100.0% 
% within Cohort Group 10.0% 6.7% 8.4% 
total Count 50 45 95 
% within Apgar - 1 52.6% 47.4% 100.0% 
% within Cohort Group 100.0% 100.0% 100.0% 
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CHART 8 
 
 
 
 
TABLE 8: APGAR 1 is highly significant among the groups.  
 
  
Baby Birth Weight
> 4.03.6-4.0<= 3.6
C
ou
nt
80
70
60
50
40
30
20
10
0
GDM
No GDM
GDM
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TABLE 9 
Apgar - 5 * Cohort Group Cross tabulation 
  
Apgar 5 
 
 
Cohort Group Total 
P 
value 
Low High   
 
 
 
 
 
0.559 
8 
 
 
Count 45 42 87 
% within Apgar - 5 51.7% 48.3% 100.0% 
% within Cohort 
Group 
90.0% 93.3% 91.6% 
9 
 
 
Count 5 3 8 
% within Apgar - 5 62.5% 37.5% 100.0% 
% within Cohort 
Group 
10.0% 6.7% 8.4% 
Total 
 
Count 50 45 95 
% within Apgar - 5 52.6% 47.4% 100.0% 
% within Cohort 
Group 
100.0% 100.0% 100.0% 
 
 CHART 10 
 
 
 
TABLE 9 : APGAR 5 is not significant between the groups. 
Apgar - 5
98
C
ou
nt
50
40
30
20
10
0
Cohort Group
Low
High
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TABLE 10 
CONGENITAL ABNORMALITY * COHORT GROUP 
Crosstab 
 
Congenital 
Abnormality 
 
Cohort Group 
Total P Value 
Low High 
Yes 
 
 
Count 0 1 1  
 
 
 
 
 
 
0.289 
% within 
Congenital 
Abnormality 
.0% 100.0% 100.0% 
% within Cohort 
Group 
.0% 2.2% 1.1% 
No 
 
 
Count 50 44 94 
% within 
Congenital 
Abnormality 
53.2% 46.8% 100.0% 
% within Cohort 
Group 
100.0% 97.8% 98.9% 
Total 
 
 
 
Count 50 45 95 
% within 
Congenital 
Abnormality 
52.6% 47.4% 100.0% 
% within Cohort 
Group 
100.0% 100.0% 100.0% 
 
 
TABLE 10: This table depicts that congenital abnormality is not 
significant. 
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TABLE 11 
PREECLAMPSIA * COHORT GROUP 
Crosstab 
 
Preeclampsia  
Cohort Group Total  
P Value Low High  
Yes 
Count 2 7 9  
 
 
 
 
 
0.050* 
% within 
Preeclampsia 
22.2% 77.8% 100.0% 
% within 
Cohort Group 
4.0% 15.6% 9.5% 
No 
Count 48 38 86 
% within 
Preeclampsia 
55.8% 44.2% 100.0% 
% within 
Cohort Group 
96.0% 84.4% 90.5% 
Total 
Count 50 45 95 
% within 
Preeclampsia 
52.6% 47.4% 100.0% 
% within 
Cohort Group 
100.0
% 
100.0% 100.0% 
 
CHART 11 
 
 
TABLE 11: This table shows preeclampsia is significant. 
Preeclampsia in low risk group is 4% and 15.6% in high risk group. 
Congenital Abnormality
NoYes
C
ou
nt
60
50
40
30
20
10
0
Cohort Group
Low
High
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TABLE 12 
SHOULDER DYSTOCIA * COHORT GROUP 
Crosstab 
 
Shoulder 
Dystocia 
 
Cohort Group 
Total 
 
P Value Low High 
Yes Count 1 7 8  
 
 
 
 
 
0.018* 
 % within Shoulder 
Dystocia 
12.5% 87.5% 100.0% 
 % within Cohort 
Group 
2.0% 15.6% 8.4% 
No Count 49 38 87 
 % within Shoulder 
Dystocia 
56.3% 43.7% 100.0% 
 % within Cohort 
Group 
98.0% 84.4% 91.6% 
Total Count 50 45 95 
% within Shoulder 
Dystocia 
52.6% 47.4% 100.0% 
% within Cohort 
Group 
100.0% 100.0% 100.0% 
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CHART 12 
 
 
 
 
TABLE 12: This table shows shoulder dystocia is significant 
between the groups. The shoulder dystocia is seen in 2% in low risk 
group and 15% in high risk group. 
  
Preeclampsia
NoYes
Co
un
t
60
50
40
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20
10
0
Cohort Group
Low
High
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TABLE 13 
RDS * COHORT GROUP CROSSTAB 
 
RDS 
 
 
Cohort Group Total 
 
P Value 
Low High 
Yes 
 
 
Count 3 23 26  
 
 
 
 
 
 
<0.001** 
% within RDS 11.5% 88.5% 100.0% 
% within Cohort Group 6.0% 51.1% 27.4% 
No 
 
 
Count 47 22 69 
% within RDS 68.1% 31.9% 100.0% 
% within Cohort Group 94.0% 48.9% 72.6% 
TOTAL Count 50 45 95 
% within RDS 52.6% 47.4% 100.0% 
% within Cohort Group 100.0% 100.0% 100.0% 
 
CHART 13 
 
 
TABLE 13 : This table shows neonatal respiratory distress 
syndrome is highly significant. The respiratory distress syndrome is 6% 
in low risk group and 51.5% in high risk group. 
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TABLE 14 
HYPOGLYCEMIA * COHORT GROUP CROSSTAB 
 
Hypoglycemia  
Cohort Group 
Total P value 
Low High 
Yes 
 
 
Count 0 13 13 
<0.001** 
% within 
Hypoglycemia 
.0% 100.0% 100.0% 
% within 
Cohort Group 
.0% 28.9% 13.7% 
No 
 
 
Count 50 32 82 
% within 
Hypoglycemia 
61.0% 39.0% 100.0% 
% within 
Cohort Group 
100.0% 71.1% 86.3% 
Total 
Count 50 45 95 
% within 
Hypoglycemia 
52.6% 47.4% 100.0% 
% within 
Cohort Group 
100.0% 100.0% 100.0% 
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TABLE 14: This table shows hypoglycemia is highly significant. 
Hypoglycemia is seen in 28.9%  in high risk group. 
 
  
RDS
NoYes
Co
un
t
50
40
30
20
10
0
Cohort Group
Low
High
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TABLE 15 
 
Perinatal Death * Cohort Group  Crosstab 
 
Perinatal Death  
Cohort Group 
Total 
Low High 
No Count 50 45 95 
 % within Perinatal 
Death 
52.6% 47.4% 100.0% 
 % within Cohort 
Group 
100.0% 100.0% 100.0% 
Total Count 50 45 95 
% within Perinatal 
Death 
52.6% 47.4% 100.0% 
% within Cohort 
Group 
100.0% 100.0% 100.0% 
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TABLE 15 : There is no perinatal death in this study. 
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C
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TABLE 16 
GDM * Cohort Group 
 
GDM  
Cohort Group 
Total 
P 
Value 
Low High 
No GDM Count 50 20 70  
 
 
 
 
 
 
<0.001
** 
 % within GDM 71.4% 28.6% 100.0% 
 % within Cohort Group 100.0% 44.4% 73.7% 
Meal plan Count 0 9 9 
 % within GDM .0% 100.0% 100.0% 
 % within Cohort Group .0% 20.0% 9.5% 
Insulin Count 0 16 16 
 % within GDM .0% 100.0% 100.0% 
 % within Cohort Group .0% 35.6% 16.8% 
TOTAL Count 50 45 95 
% within GDM 52.6% 47.4% 100.0% 
% within Cohort Group 100.0% 100.0% 100.0% 
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CHART 16 
 
 
 
 
TABLE 16 : This table shows development of GDM  among the 
study groups is highly significant. In high risk group 20%  GDM women 
was on meal plan and 35% on insulin. 
  
Perinatal Death
No
C
ou
nt
51
50
49
48
47
46
45
44
Cohort Group
Low
High
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TABLE 17 
First trimester HBA1C *GDM 
 
 N Mean 
Std. 
Deviation 
Std. 
Error 
95% Confidence 
Interval for 
Mean 
Min. Max. P Value 
     
Lower 
Bound 
Upper 
Bound   
 
 
 
<0.001** 
No 
GDM 
70 4.867 .2382 .0285 4.810 4.924 4.2 5.5 
Meal 
plan 
9 5.456 .1424 .0475 5.346 5.565 5.2 5.6 
Insulin 16 5.669 .1448 .0362 5.592 5.746 5.4 5.9 
Total 95 5.058 .3905 .0401 4.978 5.137 4.2 5.9 
 
 
CHART 17 
. 
 
 
Table  17 : This table shows association between first trimester 
Hba1c and development of GDM is highly significant. 
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TABLE 18 
 
Correlations – Low RISK COHORT only 
 
  
First 
trimester 
OGTT 
Second  
trimester 
OGTT 
Third 
Trimester 
OGTT 
First trimester 
HBA1c 
Pearson 
Correlation 
.055 .325(*) .178 
 Sig. (2-tailed) .705 .021 .216 
 N 50 50 50 
 
*  Correlation is significant at the 0.05 level (2-tailed). 
**  Correlation is significant at the 0.01 level (2-tailed). 
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TABLE 19 
Correlations – High RISK COHORT only 
 
  
First 
trimester 
OGTT 
Second  
trimeste
r OGTT 
Third 
Trimest
er 
OGTT 
First trimester 
HBA1c 
Pearson 
Correlation 
.646(**) 
.506(**
) 
.914(**) 
 Sig. (2-tailed) .000 .000 .000 
 N 50 45 41 
 
**  Correlation is significant at the 0.01 level (2-tailed). 
*  Correlation is significant at the 0.05 level (2-tailed). 
 
 
TABLE 19 : This table shows correlation between first trimester 
Hba1c and all three trimester OGTT in diagnosing GDM is highly 
significant. 
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TABLE 20 
 
First trimester HBA1C *GDM 
 
 
GDM 
 
No GDM 
GDM 
 
Mean SD Min. Max. Mean SD Min. Max 
Cohort
Group 
Low 4.82 .24 4.20 5.10 . . . . 
 
High 5.00 .18 4.80 5.50 5.59 .18 5.20 5.90 
 
 
Table 20 : This table shows First trimester Hba1c cutoff value for 
GDM development is ( 5.59 ± 0.18)% in high risk group. 
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DISCUSSION 
This study was conducted in Government RSRM lying in hospital 
with 100 pregnant women comprising of low risk group (50) and high 
risk group (50). 
First trimester HBA1C and OGTT was done and five women in 
high risk group was found to be in pregestational diabetes and they are 
excluded from the study and treated. While others are followed up till 
delivery and maternal and perinatal outcomes are studied. 
In Hughes et al study,HBA1C and OGTT are done  in antenatal 
mothers <20 weeks (WHO criteria). Women with HBA1C ≥5.9% 
(>41mmol/mol) developed diabetes and they are at increased risk of 
adverse pregnancy outcomes
3
. 
In our study, birth weight is highly significant between the two 
groups. Average birth weight in low risk group women is 2.9kg and 
3.2kg in high risk group women. 
Macrosomia is significantly associated with GDM and increased 
first trimester HBA1C levels. 
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In my study 11.6% of GDM babies weighed 3.6-4 kg and 3.2% of 
GDM babies weighed > 4 kg. 
According to Bhavadharini et al, Indian pregnant women with 
HBA1C >5.0%  are  associated with increased risk of macrosomia. In this 
study OGTT is assessed by IADSP criteria. 
In Erica bergeum et al study,early pregnancy HBA1C have utility 
in predicting third trimester GDM
37
. 
According to seshiah et al, if HBA1C is done at early weeks of 
gestation ,it will be useful to differentiate between pregestational diabetes 
and GDM. If HBA1C≥6% then it is pregestational diabetes. It may serve 
as a prognostic value . Pregnant women with normal OGTT but 
HBA1C>6% and women with HBA1Cvalues between 5.3-6% require 
utmost attention. Inspite of good glycemic control in GDM mothers, if 
HBA1C values are >6% they delivered big babies
1
. 
In my study, among the high risk group 26.3% of women 
developed GDM of which 9.5% of GDM women was on meal plan and 
16.8%was on insulin therapy. 
Thus the association between first trimester HBA1C and 
development of GDM is highly significant in high risk group. 
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After completing my study the HBA1C CUTT OFF VALUE for 
developing GDM was (5.59±0.18)% in high risk group. 
 In Amylidi et al study ,women at high risk with first trimester 
HBA1C ≥6% are predisposed to GDM. These women are at risk of 
developing diabetes mellitus and so they must be given appropriate 
advice on diet and lifestyle modifications early in pregnancy
9
. 
In Renz et al study, combination of HBA1C and OGTT 
measurements  are useful in diagnosing GDM
33
. 
In Saadati et al study,HBA1C cut off point for diagnosing GDM 
before 20 weeks of pregnancy is 5.5%. The association between HBA1C 
changes in diagnosing GDM before 20 weeks and BMI are highly 
significant
38
. 
In khalafallah et al study, if HBA1C ≥5.4% then pregnant women 
should proceed with OGTT, thus reducing the burden of testing on 
patients, staffs and resources
8
. 
Ingrid hov et al study was conducted in women with PCOS. 
According to this study, first trimester HBA1C is a better predictor of 
preeclampsia than GDM
35
. 
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In my study, development of Preeclampsia is significant between 
the two groups. 4% women in low risk group developed preeclampsia 
while 15.6% women in high risk group developed preeclampsia. 
Ingrid hov et al study was conducted in Nordic Caucasian women. 
GDM was diagnosed by WHO/modified IADPSG criteria at pregnancy 
weeks 18-22 and 32-36 weeks. This study concluded that HBA1C could 
potentially reduce the number of OGTT testing
34
.  
SUMMARY 
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SUMMARY 
This study was conducted in Government RSRM lying in hospital 
with 100 pregnant women comprising of low risk group (50) and high 
risk group(50). 
First trimester HBA1C and OGTT was done and 5 women in high 
risk group was found to be in pregestational diabetes and they are 
excluded from the study and treated. While others are followed up till 
delivery and maternal and perinatal outcomes are studied. 
Among the high risk group 26.3% women developed GDM of 
which 9.5% was on meal plan and 16.8% on insulin therapy. 
Thus association between first trimester HBA1C and development 
of GDM is highly significant. 
HBA1C CUTT OFF VALUE=(5.59±0.18)% 
The mean age group in low risk group is 22 yrs and 26 yrs in high 
risk group. 
The mean BMI in low risk group is 23.12 and 26.44 in high risk 
group. 
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The mode of delivery is not significant between the two groups. 
Pregnant  women in low risk group delivered by LSCS is 38%and by 
labour natural is 6.2%.Pregnant women in  high risk women delivered by 
LSCS is 51%,labour natural is 46.7% and outlet 2.2%. 
Baby birth weight is highly significant between the groups.Mean 
birth weight in low risk women is 2.9 kg and 3.2 kg in high risk women. 
Macrosomia is significantly associated with GDM and increased 
first trimester HBA1C levels.11.6% GDM babies weighed3.6-4 kg and 
3.2% babies weighed > 4 kgs.   
APGAR  1 minute is highly significant between the groups. 
Preeclampsia is significantly associated between the groups .4% 
women in low risk group developed preeclampsia while 15.6% women in 
high risk developed preeclampsia. 
Shoulder dystocia is significant between the groups.2% in low risk 
developed shoulder dystocia and 15.6% in high risk developed shoulder 
dystocia. 
Respiratory distress syndrome developed significantly in high risk 
group.51.1% babies born to high risk women developed respiratory 
distress syndrome while 6% babies in low risk group developed 
respiratory distress syndrome. 
CONCLUSION 
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CONCLUSION 
First trimester HBA1C ≥5.5% in high risk group is useful in 
predicting pregnant women who develops GDM, so they must be given 
appropriate advice of diet  and  lifestyle modification early in pregnancy. 
Respiratory distress syndrome, shoulder dystocia, hypoglycemia, 
APGAR 1 minute, preeclampsia, macrosomia are highly significant 
between the groups  with HBA1C ≥5.5% 
Thus first trimester HBA1C helps in predicting adverse maternal 
and fetal outcomes. 
It  also identifies women with pre-gestational diabetes. 
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ANNEXURE 
PROFORMA 
                                                                                                                         
DATE: 
NAME:                                                                            
AGE:                        
LOW RISK/HIGH RISK COHORT:                                                                                                               
D.O.A:                
D.O. Delivery:                              
D.O. Discharge  
LMP: 
EDD:                                
OBSTETRIC CODE: 
GESTATIONAL AGE: 
 
ADDRESS & CONTACT NO:                                                                            
 
PRESENTING  COMPLAINTS: 
 
 
MENSTRUAL  HISTORY :                                                                                             
MD SINCE: 
OBSTETRIC HISTORY: 
 
 
PAST HISTORY             
FAMILY HISTORY       
GENERAL EXAMINATION  : 
 
HEIGHT 
WEIGHT 
BMI 
ANEMIA 
EDEMA 
PULSE 
BP 
CVS 
RS 
 
 
OBSTETRIC EXAMINATION  : 
 
P/A EXAMINATION 
 
P/V EXAMINATION 
 
 
 
 
DATE AND TIME OF DELIVERY  
 
MODE OF DELIVERY 
VAGINAL DELIVERY 
SHOULDER DYSTOCIA 
IF LSCS, INDICATION   FOR LSCS                                                     
TERM/PRETERM 
BABY SEX 
BIRTH WEIGHT 
APGAR 
COMPLICATIONS 
INVESTIATIONS 
IST TRIMESTER 
HB- 
HBA1C 
OGTT 
BLOOD GROUP 
URINE ALBUMIN/SUGAR 
DATING SCAN 
NT SCAN 
II ND TRIMESTER 
HB 
OGTT 
ANOMALY SCAN 
URINE ALBUMIN/SUGAR 
III TRIMESTER 
OGTT 
GROWTH SCAN  
URINE ALBUMIN/SUGAR. 
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1 DEVI 33 3982 HIGH G2A1 4.8 112 114 112 
OUTLET 
FORCEPS 
2.705 7,8 NO NO NO YES NO NO NO 
2 MUTHUPRIYA 21 4012 LOW PRIMI 4.2 82 80 84 LN 2.44 7,8 NO NO NO NO NO NO NO 
3 BHAVANI 23 3245 HIGH G2P1L1 4.5 150 Excluded from Study 
4 MANIMEGALAI 21 4016 LOW G2P1L1 4.9 113 89 101 LN 3.005 8,9 NO NO NO NO NO NO NO 
5 JEYANTHI 20 4011 LOW PRIMI 4.5 86 89 86 LN 3.64 7,8 NO NO NO NO NO NO NO 
6 SARASWATHY 29 3887 HIGH G2P1L1 5.4 72 76 156 LN 3.2 7,8 NO NO NO NO NO NO MNT 
7 MADHAVI 25 4023 LOW G3P2L2 4.4 126 95 64 LN 2.56 7,8 NO NO NO NO NO NO NO 
8 SHAKIRA 19 4024 HIGH PRIMI 5.6 98 96 163 LN 2.465 7,8 NO NO NO YES NO NO MNT 
9 JEYAPRADHA 25 4022 LOW G3P1L1A1 5 90 98 128 LN 3.175 7,8 NO NO NO NO NO NO NO 
10 UMMUL HABIBA 25 3935 HIGH G2P1L1 5.7 120 156 178 LSCS 4 7,8 NO YES NO YES YES NO INSULIN 
11 KARTHIGAISELVI 33 3971 HIGH G2P1L1 5.5 118 126 150 LSCS 3.6 7,8 NO NO NO NO NO NO MNT 
12 SABITHA 29 4048 HIGH G3P1L1A1 5.7 92 91 144 LSCS 3.41 8,9 NO YES NO NO NO NO INSULIN 
13 SURYAKALA 25 4080 HIGH PRIMI 5 96 99 99 LN 3.44 8,9 NO NO NO NO NO NO NO 
14 POOMATHI 22 3543 LOW G2P1L1 5 98 98 98 LSCS 2.46 7,8 NO NO NO NO NO NO NO 
15 SIVABALA 26 4081 LOW G2A1 5.1 90 99 98 LN 2.45 7,8 NO NO NO NO NO NO NO 
16 BHAVANI 22 4072 LOW PRIMI 5 92 94 95 LSCS 3.47 8,9 NO NO NO NO NO NO NO 
17 SUNATHA 20 3791 LOW PRIMI 5.1 98 96 98 LSCS 2.37 7,8 NO NO NO NO NO NO NO 
18 NIRMALA 22 4049 HIGH PRIMI 5.6 94 98 161 LN 3.25 7,8 NO NO NO NO NO NO MNT 
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19 SARALA 20 4032 LOW PRIMI 4.8 98 89 92 LSCS 2.84 7,8 NO NO NO NO NO NO NO 
20 SHAKIRA 19 4024 LOW PRIMI 5 85 87 78 LN 2.465 7,8 NO NO NO NO NO NO NO 
21 RAJALAKSHMI 20 3805 HIGH G2P1L1 5.6 89 120 173 LSCS 2.305 7,8 NO YES NO YES YES NO INSULIN 
22 NASEEMABEGUM 21 3245 HIGH G2P1LO 5.4 78 100 156 LSCS 2.845 7,8 NO NO NO YES YES NO INSULIN 
23 ANITHA 28 3453 HIGH G3P1L1A1 5.8 66 123 167 LN 3.9 7,8 NO NO YES YES NO NO INSULIN 
24 UMA MAHESWARI 24 3439 LOW G2P1L1 4.9 76 124 87 LSCS 2.525 8,9 NO NO NO NO NO NO NO 
25 KEERTHANA 19 4051 LOW PRIMI 5.1 78 98 86 LN 3.74 7,8 NO NO NO NO NO NO NO 
26 SAMEERA 26 4035 LOW G2P1L1 5 86 88 90 LN 3.7 7,8 NO YES YES NO NO NO NO 
27 YUVARANI 23 4017 LOW PRIMI 4.4 92 89 98 LN 3.25 7,8 NO YES NO NO NO NO NO 
28 FAMITHA 19 6267 LOW PRIMI 4.8 90 98 99 LSCS 3.04 7,8 NO NO NO NO NO NO NO 
29 DILLIRANI 20 6188 LOW PRIMI 4.4 65 78 98 LN 2.5 7,8 NO NO NO NO NO NO NO 
30 YUVARANI 22 8339 LOW G2P1L1 4.5 63 65 68 LSCS 2.855 7,8 NO NO NO NO NO NO NO 
31 ANANDHI 33 8677 HIGH PRIMI 7 167 Excluded from Study 
32 SOWMIYA 19 8471 LOW PRIMI 4.7 89 97 87 LN 3.015 7,8 NO NO NO NO NO NO NO 
33 SHAHIDA 24 8128 HIGH PRIMI 4.9 90 96 95 LSCS 2.55 7,8 NO NO NO NO NO NO NO 
34 VISITHRA 20 8479 HIGH PRIMI 5 89 87 88 LSCS 2.44 7,8 NO NO NO NO NO NO NO 
35 SANDHIYA 20 7924 HIGH PRIMI 4.8 65 96 96 LSCS 2.9 7,8 NO NO NO YES NO NO NO 
36 
SYED ALI 
FATHIMA 
25 8578 LOW G2A1 4.5 76 73 76 LSCS 3.3 6,8 NO NO NO YES NO NO NO 
37 DEEPAPRIYA 19 8377 LOW PRIMI 4.8 78 77 98 LSCS 3.45 7,8 NO NO NO NO NO NO NO 
38 RESHMA 20 7866 LOW PRIMI 5 78 86 88 LSCS 3.415 7,8 NO NO NO YES NO NO NO 
39 NAVEENA 21 6757 LOW G2P1L1 4.4 87 88 90 LN 2.775 7,8 NO NO NO NO NO NO NO 
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40 USHA 26 6779 HIGH G4P1L0A2 4.8 88 89 76 LN 2.13 7,8 NO NO NO YES NO NO NO 
41 PRIYANKA 22 4002 LOW PRIMI 5 90 88 83 LSCS 3.26 7,8 NO NO NO NO NO NO NO 
42 LALITHA 28 5661 HIGH G2A1 4.9 98 76 85 LSCS 2.9 8,9 NO NO NO NO NO NO NO 
43 DURGADEVI 22 6788 HIGH G3A2 5.7 117 114 165 LSCS 1.935 7,8 NO YES NO YES YES NO INSULIN 
44 ABIRAMI 22 3996 HIGH PRIMI 5.2 114 109 138 LN 2.965 7,8 NO NO NO NO NO NO NO 
45 UMA MAHESWARI 26 3272 HIGH G2P1L1 5.5 109 120 160 LSCS 3.654 7,8 NO NO NO YES YES NO INSULIN 
46 DURGA 27 3073 HIGH G3P2L1 5.1 108 112 123 LN 2.543 7,8 NO NO NO NO NO NO 
NO 
47 YASODHA 30 5789 HIGH G2P1L1 7 165 
Excluded from Study 
48 SARANYA 22 3656 LOW G2P1L1 4.5 82 98 114 LN 2.987 7,8 NO NO NO NO NO NO 
NO 
49 CHITRA 28 3555 HIGH G3A2 4.8 143 
Excluded from Study 
50 GOMATHI 21 3566 LOW PRIMI 5 89 98 78 LN 2.678 7,8 NO NO NO NO NO NO 
NO 
51 MADHUSHARMA 26 7656 HIGH PRIMI 5.4 99 78 162 LN 3.9 6,8 NO NO YES YES NO NO MNT 
52 PRIYANKA 23 4777 LOW PRIMI 4.9 87 99 89 LN 2.7 7,8 NO NO NO NO NO NO 
NO 
53 MAIJOONBEEVI 26 3186 HIGH G4P1L1A2 10.3 212 
Excluded from Study 
54 NATHIYA 27 3487 HIGH G2P1L1 5.1 102 112 108 LSCS 2.2 7,8 NO NO NO NO NO NO 
NO 
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55 ANOTHA 26 7868 LOW G2P1L1 4.6 108 93 98 LSCS 2.635 7,8 NO NO NO NO NO NO 
NO 
56 PARVEEN BANU 21 4010 LOW PRIMI 5 76 98 87 LSCS 2.53 7,8 NO NO NO NO NO NO 
NO 
57 NAVEENA 21 3990 LOW G2P1L1 4.8 87 90 90 LN 2.725 8,9 NO NO NO NO NO NO 
NO 
58 USHA 24 3897 LOW G4P1L1A2 5.1 109 98 108 LN 2.13 7,8 NO NO NO YES NO NO 
NO 
59 SHALINO 22 5656 LOW PRIMI 4.5 99 89 95 LN 2.78 7,8 NO NO NO NO NO NO 
NO 
60 DURGADEVI 22 3942 LOW PRIMI 4.8 100 98 90 LN 3.2 7,8 NO NO NO NO NO NO 
NO 
61 MAHALAKSHMI 21 5673 LOW PRIMI 5 102 87 80 LSCS 2.825 7,8 NO NO NO NO NO NO 
NO 
62 JAMILA 22 6268 HIGH G3P2L2 5.6 108 106 168 LSCS 4  7,8 NO YES NO YES YES NO INSULIN 
63 ADHILAKSHMI 24 7838 LOW G2P1L1 5 102 108 105 LN 2.9 7,8 NO NO NO NO NO NO 
NO 
64 UMA MAHESWARI 23 5657 LOW PRIMI 4.5 85 87 84 LN 3.4 7,8 NO NO NO NO NO NO 
NO 
65 VALLIYAMMAL 22 7657 LOW PRIMI 4.9 74 89 96 LN 3.2 7,8 NO NO NO NO NO NO 
NO 
66 MANOMEGALAI 23 8678 LOW G2P1L1 4.8 102 97 96 LN 3.256 7,8 NO NO NO NO NO NO 
NO 
67 JANANI 22 6887 HIGH PRIMI 5.8 109 105 178 LSCS 4.2 6,8 NO YES YES YES YES NO INSULIN 
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68 RAMYA 25 8732 LOW G2P1L1 5.1 76 99 87 LN 3.2 8,9 NO NO NO NO NO NO 
NO 
69 KALPANA 23 7878 LOW PRIMI 4.9 72 76 87 LN 3.015 7,8 NO NO NO NO NO NO 
NO 
70 MEENATCHI 22 4534 LOW PRIMI 4.6 89 96 94 LN 2.98 7,8 NO NO NO NO NO NO 
NO 
71 MAHALAKSHMI 21 7546 LOW G2P1L1 4.7 102 94 84 LSCS 3.1 7,8 NO NO NO NO NO NO 
NO 
72 DHANALAKSHMI 24 9985 LOW G4P1L1A2 5 101 102 90 LSCS 2.85 7,8 NO NO NO NO NO NO 
NO 
73 HEMALATHA 25 5934 LOW G3P1L1A1 4.9 76 78 95 LN 2.76 7,8 NO NO NO NO NO NO 
NO 
74 VINITHRA 21 3006 LOW PRIMI 4.8 85 84 86 LSCS 3.4 7,8 NO NO NO NO NO NO 
NO 
75 SUMITHRA 18 8006 LOW G2A1 5 90 97 74 LN 3.098 7,8 NO NO NO NO NO NO 
NO 
76 DHANAM 24 9596 LOW G2P1L1 5.1 98 90 92 LSCS 2.96 7,8 NO NO NO NO NO NO 
NO 
77 YASODHA 22 1282 LOW G3P1L1A1 4.9 97 84 73 LSCS 3.25 7,8 NO NO NO NO NO NO 
NO 
78 BRINDHA 19 8566 LOW PRIMI 4.8 96 94 102 LN 3 7,8 NO NO NO NO NO NO 
NO 
79 SAKTHI 23 5129 LOW PRIMI 5.1 75 74 103 LN 2.9 7,8 NO NO NO NO NO NO 
NO 
80 ZEENATH 22 7687 HIGH G2A1 5.3 98 98 153 LN 3.3 7,8 NO NO NO YES NO NO MNT 
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81 JANSIRANI 24 5688 HIGH PRIMI 5.5 100 102 154 LN 3.15 7,8 NO NO NO NO NO NO MNT 
82 CHITRA 23 4365 HIGH G3A2 5.4 97 132 167 LSCS 3.8 7,8 NO YES NO YES YES NO INSULIN 
83 FATHIMA 30 8823 HIGH G2P1L1 5.2 102 122 156 LSCS 3.7 6,8 NO NO NO YES NO NO MNT 
84 RAJESWARI 27 9344 HIGH PRIMI 5.9 94 154 NO LSCS 4.12 6,8 NO NO NO YES YES NO INSULIN 
85 ALAMELU 28 7829 HIGH G3P1L1A1 5 103 129 111 LN 2.9 7,8 NO NO NO NO NO NO 
NO 
86 GURUSAKYA 29 7834 HIGH PRIMI 5.1 114 108 120 LN 3.12 7,8 NO NO NO NO NO NO 
NO 
87 SANGEETHA 32 9475 HIGH G3P2L2 5.5 109 112 160 LN 3.5 6,8 NO NO YES YES YES NO 
NO 
88 THIRUMATHI 28 5738 HIGH G2P1L1 5.7 98 160 NO LSCS 4.2 5,8 YES YES YES YES YES NO INSULIN 
89 SIVABALA 30 9747 HIGH G3P1L1A1 5.6 102 130 170 LN 3.14 7,8 NO NO NO NO NO NO MNT 
90 GAYATHRI 22 8392 HIGH PRIMI 5.8 78 124 180 LN 3.6 6,8 NO NO YES YES YES NO INSULIN 
91 SARANYA 28 7409 HIGH G2A1 5.7 116 160 NO LSCS 3.5 6,8 NO NO NO YES NO NO INSULIN 
92 KUMARI 28 8934 HIGH PRIMI 4.8 102 112 113 LN 2.87 7,8 NO NO NO NO NO NO 
NO 
93 AMALA 31 7434 HIGH G2P1L1 5.2 113 101 134 LN 2.65 7,8 NO NO NO NO NO NO 
NO 
94 NOVEDHA 24 8494 HIGH PRIMI 4.9 98 97 123 LN 2.9 7,8 NO NO NO NO NO NO 
NO 
95 SARANYA 26 9565 HIGH G2A1 4.9 98 95 108 LN 3.1 7,8 NO NO NO NO NO NO 
NO 
96 ABIRAMI 29 4152 HIGH PRIMI 5.1 110 120 118 LSCS 3.2 7,8 NO NO NO NO NO NO 
NO 
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97 KAVYA 32 5623 HIGH G2P1L1 5.8 98 156 NO LN 3.65 6,8 NO NO YES YES YES NO INSULIN 
98 SABITHA 33 9204 HIGH G4P1L1A2 4.8 97 98 103 LSCS 3.63 7,8 NO NO NO NO NO NO NO 
99 MALAR 29 8093 HIGH PRIMI 5 102 104 123 LSCS 345 7,8 NO NO NO NO NO NO NO 
100 PRIYA 32 945 HIGH G2P1L1 5.6 102 112 176 LSCS 3.9 6.8 NO NO NO YES NO NO INSULIN 
 
 
 
ABBREVATIONS 
GDM  - Gestational Diabetes Mellitus 
WHO  - World Health Organization 
OGTT - Oral Glucose Tolerance Test 
DIPSI - Diabetes In Pregnancy Study Group India 
ACOG - American Congress Of Obstetricians And   
   Gynecologists 
IUD  - Intrauterine Death 
HBA1C - Glycosated Hemoglobin 
IADSP - International Association Of Diabetes And Pregnancy 
   Study Groups 
MNT  - Medical Nutrition Therapy 
DM  - Diabetes Mellitus 
ADA  - American Diabetes Association 
HAPO - Hyperglycemia And Adverse Pregnancy Outcome 
  
CONSENT FORM 
I  agree to participate in the study entitled ‘I confirm that I have 
been told about this study “DETERMINATION OF RELATIONSHIP 
BETWEEN  FIRST TRIMESTER HBA1C LEVELS AND EARLY 
DIAGNOSIS OF GESTATIONAL DIABETES MELLITUS” in my 
mother tongue and have had the opportunity to clarify my doubts. 
I understand that my participation  is voluntary and I may refuse to 
participate at any time without  giving any reasons and without affecting 
my benefits. 
I agree not to restrict the use  of any data or results that arise from 
this study. 
 
Name of the Participant : 
Sign / Thumb print: 
Name of the investigator: Dr.T.Janani 
Sign of Investigator : 
 
  
�ய ஒப்�தல் ப�வம் 
 
“�தல் �ன்� மாதம் கிைளேகாைஸேலடட் 
இரத்தச்சிவப்ப�க்கள�ன் அள�ம் அதன் கர்ப்பகால ந� ழி� 
ேநாய் கண்டறி�ம் இயல்�ம் பற்றிய ஆய்�.” 
 
ஆய்வாளர் : ம�.த.ஜனன�  
   ��நிைல பட்ட ேமற்ப�ப்� மாணவர் 
   மகப்ேப� மற்றம் ெபண்கள் நலத்�ைற 
   ஆர்.எஸ்.ஆர்.எம்.ம�த்�வமைன 
   ஸ்டான்லி ம�த்�வ கல்�� – ெசன்ைன 
        
 
ெபயர் :           வய� :        உள்ள� ப்� எண் : 
 
இந்த ம�த்�வ ஆய்வ�ன் வ�வரங்கள் எனக்� 
வ�ளக்கப்பட்ட� என்�ைடய சந்ேதகங்கைள த�ர்க்க�ம் 
அதற்கான த�ந்த வ�ளக்கங்கைள ெபற�ம் வாய்ப்பள�க்கப்பட்ட� 
 நான் இவ்வாய்வ�ல் தன்ன�ச்ைசயாகத்தான் பங்ேகற்கிேறன். 
எந்த காரணத்தினா�ம் எந்த கட்டத்தி�ம் எந்த சட்டசிக்க�ம் 
இன்றி இந்த ஆய்வ�லி�ந்� வ�லகிக் ெகாள்ளலாம் என்�ம் 
அறிந்� ெகாண்ேடன். 
 நான் ஆய்வ�லி�ந்� வ�லகிக்ெகாண்டா�ம் ஆய்வாளர் 
என்�ைடய ம�த்�வ அறிக்ைககைள பார்ப்பதற்ேகா அல்ல� 
உபேயாகிக்கேவா என் அ�மதி ேதைவய�ல்ைல என�ம் அறிந்� 
ெகாண்ேடன் என்ைன பற்றிய தகவல்கள் ரகசியமாக 
பா�காக்ப்ப�ம் என்பைத�ம் அறிேவன். 
 இந்த ஆய்வ�ன் �லம் கிைடக்�ம் தகவல்கைள�ம் 
ப�ேசாதைன ���கைள�ம் ஆய்வாளர் அவர் 
வ� ப்பத்திற்ேகற்ப பயன்ப�த்திக் ெகாள்ள�ம் அதைன 
ப�ர��க்க�ம் ��மன�டன் சம்மதிக்கிேறன். 
 இந்த ஆய்வ�ல் பங்� ெகாள்ள ஒப்�க்ெகாள்கிேறன் எனக்� 
ெகா�க்கப்பட்�ள்ள அறி�ைரகள�ன்ப� நடந்� ெகாள்வ�டன் 
ஆய்வாள�க்� உண்ைம�டன் இ�ப்ேபன், என்�ம் உ�தி 
அள�க்கிேறன். 
 உடல்நலம் பாதிக்கப்பட்டாேலா வழக்கத்திற்� மாறான 
ஏேத�ம் ேநாய்�றி ெதன்பட்டாேலா அதைன ெத�வ�ப்ேபன் 
என்�ம் உ�தி ��கிேறன். 
 இந்த ஆய்வ�ல் எனக்� எவ்வ�தமான ப�ேசாதைனகைள�ம் 
சிகிச்ைசகைள�ம் ேமற்ெகாள்ள நான் ��மன�டன் 
சம்மதிக்கிேறன். 
 
    இப்ப�க்�, 
 
                                                           
ேநாயாள�ய�ன்  ைகெயாப்பம்       ஆய்வாள�ன் ைகெயாப்பம் 
 
 

